Solid organ transplantation (SOT) was for a long time contraindicated in HIV-positive patients for fear of infectious complications. 3 In the past decade, favorable outcomes have been reported for kidney transplantation in HIV-positive patients with a 3-year survival rate of 94% while liver transplantation success has been limited by HCV recurrence with a 3-year survival rate of 64%. 4, 5 Based on these studies, HIV status was no longer considered as an absolute contraindication for lung transplantation. 6 However, published cases of lung transplantation in HIV-infected patients remain scarce. [7] [8] [9] Nontuberculous mycobacterial (NTM) disease is also becoming a worldwide cause for chronic pulmonary infection. In the era of HAART, it is estimated that less than 2% of HIV-infected patients have NTM disease. 10 NTM disease may influence the clinical posttransplant evolution in patient undergoing lung transplantation as some data showed an increased risk of recurrence or post-transplant infections. 6 Currently, recommendations do not contraindicate lung transplantation in these cases but clinicians must be aware of the risk involved, especially with some NTM species or multidrug resistant strains. 11 No data exists on the impact of pretransplant NTM isolated from the lungs of HIV-infected patients on post-transplant course. Therefore, we report a case of a double lung transplantation in an HIV-positive patient with NTM lung infection.
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A 50-year-old man having sex with men was diagnosed with HIV 
| D ISCUSS I ON
An update of the Pulmonary Transplantation Council of the ISHLT states that carefully selected HIV-positive patients can be candidates for lung transplantation. 6 Data from kidney and liver transplantation have shown favorable outcomes in HIV-infected patients. 4, 5 However, reported experience in lung transplantation remains scarce. Review of literature of lung transplantation in HIV-infected patients is included in Table 1 . A major concern about SOT in the HIV-infected population is drug-drug interactions. Antiretrovirals, especially protease inhibitors, are powerful cytochrome inhibitors that affect the metabolism of immunosuppressive drugs such as tacrolimus or cyclosporine making their adjustment quite challenging. [12] [13] [14] Hence, inadequate exposure to immunosuppressive drugs with subtherapeutic serum levels may lead to graft rejection in the patient.
14 Our patient was already on an integrase inhibitor regimen when referred for transplant evaluation. Therefore, we did not have to change his ART regimen to minimize drug-drug interactions.
Although 2-hour post-cyclosporine dose levels were irregular and dose management was difficult in early post-transplantation, no clinically significant drug interaction was reported. Nevertheless, low-grade acute rejection was reported at 6 months post-transplant which was successfully treated with corticosteroids. In the case series of Kern et al, all three patients experienced acute cellular rejections that were treated successfully with methylprednisolone. One corticosteroid-resistant episode was treated with anti-thymocyte globulins but unfortunately evolved toward BO. All three patients experienced significant drug-drug interactions but dose adjustments were well managed making the exact cause of rejection unknown. 7 Although, it is estimated that 30% of lung transplant recipients experience acute cellular rejection, 15 we know through other SOT cohorts that HIV-infected patients present a higher relative risk of acute rejection compared to their Furthermore, management of therapy also varies depending on the species. Empiric treatment for M. kansasii includes ethambutol, isoniazid, and rifampin. As management of HIV in SOT is complicated by drug-drug interactions between ART and immunosuppressants, the addition of rifampin just increases the complexity of overall drug management. 21 Our patient had documented necrotizing granuloma secondary to NTM on the pathology of native lungs after transplantation. Expectative management was decided for many reasons. First, a negative pre-transplant intradermic tuberculin test was reassuring as tuberculosis was less likely probable. 22 Second, when pathology results became available, no NTM had grown from native lungs specimens. 
